| Zacks Company Profile for Amicus Therapeutics, Inc. (FOLD : NSDQ) |
|
|
| |
| • Company Description |
| Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Number of Employees: 499 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $6.09 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,102,476 shares |
| Shares Outstanding: 307.93 (millions) |
| Market Capitalization: $1,875.30 (millions) |
| Beta: 0.51 |
| 52 Week High: $12.65 |
| 52 Week Low: $5.51 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
1.00% |
-3.57% |
| 12 Week |
-10.84% |
-24.75% |
| Year To Date |
-35.35% |
-39.26% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Bradley L. Campbell - President and Chief Executive Officer
John F. Crowley - Executive Chairman
Simon Harford - Chief Financial Officer
Margaret G. McGlynn - Director
Michael G. Raab - Director
|
|
Peer Information
Amicus Therapeutics, Inc. (CORR.)
Amicus Therapeutics, Inc. (RSPI)
Amicus Therapeutics, Inc. (CGXP)
Amicus Therapeutics, Inc. (BGEN)
Amicus Therapeutics, Inc. (GTBP)
Amicus Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03152W109
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 307.93
Most Recent Split Date: (:1)
Beta: 0.51
Market Capitalization: $1,875.30 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.04 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $0.02 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 4.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
